Renal Medication Safety: Dose, Reconcile, Reassess

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Renal prescribing is a repeated process: choose the correct clearance estimate, recognize accumulation, and update the plan when physiology changes.

Reduced clearance can increase drug exposure. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Reduced clearance can increase drug exposure. Medicine enters — Dose, formulation and interactions; Circulating drug — Exposure depends on clearance; Kidney elimination — Changing function alters accumulation; Review and monitor — Revisit dose, toxicity, holds and restart. Accumulation and direct kidney injury are different mechanisms; review both. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Match the estimate to the drug

Check whether the label uses creatinine clearance, indexed eGFR, or another method. At body-size extremes, indexed mL/min/1.73 m² differs from absolute mL/min. When a small error changes a high-risk dose, use a more accurate assessment and pharmacist review.

Changing creatinine means changing exposure

Steady-state eGFR can mislead during AKI and recovery. Review the next maintenance dose using the trend, urine output, drug levels when available, and dialysis delivery. A necessary loading dose is a separate decision from the maintenance interval.

Know the toxicity clues

Gabapentinoids or baclofen can cause sedation and myoclonus; cefepime can cause encephalopathy or seizures; accumulating anticoagulants can cause bleeding. New symptoms after a dose change should trigger a medication review before adding another drug to suppress them.

Catch dangerous combinations

NSAID + diuretic + RAAS blockade can precipitate hemodynamic AKI. Trimethoprim plus RAAS/MRA therapy increases hyperkalemia risk. Azathioprine plus xanthine-oxidase inhibition can cause severe myelosuppression: febuxostat is contraindicated, not a safer substitute for allopurinol.

Plan holds AND restarts

Specify the drug, illness trigger, contact route, and restart criteria. SGLT2 inhibitors are usually withheld during prolonged fasting, surgery, or critical illness. A temporary hold should not become permanent omission once intake, hemodynamics, and kidney function are reassessed.

Close every transition

At admission, dialysis initiation, discharge, and recovery, reconcile indication, dose, timing, interactions, and OTC products. Document the next laboratory test and responsible clinician. Include dialysis-session timing for dialyzable drugs and residual kidney function when relevant.

Supporting evidence

Continue learning